Anthera Pharmaceuticals, Inc.
ANTH · OTC
12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | -95.4% | – | – |
| Gross Profit | -$0 | $0 | $0 | -$0 |
| % Margin | – | 68.1% | 99% | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -39,249% | -1,097.6% | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -36,967.6% | -1,096.1% | – |
| EPS Diluted | -1.65 | -10.38 | -7.84 | -11.13 |
| % Growth | 84.1% | -32.4% | 29.6% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |